Streptoniazid is a streptomycin derivative patented by Societe des usines chimiques de Rhone-Poulenc as antibiotic effective against tuberculosis.

Mirincamycin, a protein biosynthesis inhibitor was studied as an antibacterial agent. It was shown that mirincamycin could be promising candidate in the therapy and prophylaxis of multidrug-resistant falciparum malaria. Moreover, in combination with 4 or 8-aminoquinolines it could be used for the treatment and relapse prevention of vivax malaria. In addition, was studied the anti-relapse activity of mirincamycin in the Plasmodium cynomolgi sporozoite-infected Rhesus monkey model. However, the negative P. cynomolgi hypnozoite data indicates that mirincamycin is unlikely to have potential as a clinical anti-relapse agent.

Maridomycin is a macrolide antibiotic. Sreptomyces sp. No. B-5050 was found to produce maridomycin. Maridomycin was found to be composed of six components, maridomycins I, II, III, IV, V and VI. Their structures are different from each other in acyl moieties at C3 and C4" positions. Maridomycins I, II, III, IV, V and VI showed similar antibacterial spectra against Gram-positive bacteria including acid-fast bacteria. Maridomycin has bacteriostatic activity rather than bactericidal activity. Prominent therapeutic effect was observed against certain Gram-positive bacterial infection in mice.

Rolicyprine (EX-4883) is an antidepressant. This compound is a potent inhibitor of monoamine oxidase in vivo. One study found that rolicyprine must be biotransformed before it is a pharmacologically active compound. Once it is activated, Rolicyprine appears to have a pharmacology like that of the antidepressant tranylcypromine. It was suggested that the products of this biotransformation are tranylcypromine and pyrrolidone carboxylic acid. No information on current use of rolicyprine is available.

Carubicin (also known as Carminomycin) is an anthracycline antineoplastic antibiotic isolated from the bacterium Actinomadura carminata. Carubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. The drug is active against a variety of experimental tumors. Pharmacology studies in animals revealed that the drug bound largely to serum proteins and that it was widely distributed. In clinical trials The main toxic effect was myelosuppression but gastrointestinal intolerance and alopecia were also reported. Objective partial responses were seen in two of seven previously untreated patients with non-small cell lung cancer and one of three patients with squamous cell carcinoma of the head and neck previously untreated with chemotherapy.

FLOVAGATRAN is a potent, reversible, low-molecular-weight, highly selective synthetic direct thrombin inhibitor that has demonstrated promising pharmacokinetic properties and biological activity in preclinical studies. However, its development for thrombosis was discontinued in Phase II.

Ociltide (also known as Hoe 825), an enkephalin peptide that via inhibition of the inhibitory nervous system could influence on esophageal motility, fundic accommodation to distention, and migrating myoelectric complex. Information about the current development of this drug is not available.